Jasper Therapeutics, Inc. (JSPR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jasper Therapeutics, Inc., a Delaware corporation and emerging growth company, on June 9, 2026, regarding an event dated June 3, 2026. The Company's voting common stock (JSPR) and redeemable warrants (JSPRW) are listed on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes and Events
- Nasdaq Non-Compliance Notice: On June 3, 2026, the Company received written notice from Nasdaq stating that its common stock bid price closed below the minimum $1.00 per share requirement for 30 consecutive business days.
- Compliance Period: The Company has been granted an initial 180-day period, ending November 30, 2026, to regain compliance.
- Compliance Criteria: To cure the deficiency, the bid price must close at $1.00 or more for a minimum of ten consecutive business days before the deadline.
- Trading Status: The notice has no immediate effect on the listing or trading of the Company's securities; they will continue to trade under symbols JSPR and JSPRW.
Outlook, Risks, and Management Commentary
Management intends to monitor the bid price and consider available options to regain compliance, which may include effectuating a reverse stock split. If the Company fails to regain compliance by November 30, 2026, it may be eligible for an additional 180-day period, provided it meets other listing standards (excluding the bid price) and notifies Nasdaq of its intent to cure, potentially via a reverse stock split.
Risks and Contingencies:
- There is no assurance the Company will meet the bid price requirement or other listing standards.
- There is no assurance Nasdaq will grant any request for continued listing or relief from delisting.
- If the Company cannot cure the deficiency or is deemed ineligible for an extension, its securities may be subject to delisting.
Investor Verification Checklist
- Verify the current bid price of JSPR to assess the likelihood of meeting the $1.00 threshold within the 180-day window.
- Review the Company's most recent Form 10-K and 10-Q for cash position and liquidity to evaluate the feasibility of a reverse stock split or other capital actions.
- Monitor future press releases for announcements regarding a reverse stock split or formal appeals to Nasdaq.
- Check the market value of publicly held shares to determine eligibility for a second compliance period if the first is missed.